Skip to main content
Erschienen in: Virchows Archiv 4/2018

21.07.2018 | Original Article

Activity and clinical relevance of autotaxin and lysophosphatidic acid pathways in high-grade serous carcinoma

verfasst von: Hadil Onallah, Liora Jacobs Catane, Claes G. Tropé, Thea E. Hetland Falkenthal, Reuven Reich, Ben Davidson

Erschienen in: Virchows Archiv | Ausgabe 4/2018

Einloggen, um Zugang zu erhalten

Abstract

The aim of this study was to analyze the expression, biological role and clinical relevance of autotaxin (ATX), the enzyme synthetizing lysophosphatidic acid (LPA), and LPA receptors (LPAR) in high-grade serous carcinoma (HGSC). mRNA expression by qRT-PCR of LPAR1-6 was analyzed in 155 HGSC specimens (88 effusions, 67 solid lesions). ATX mRNA expression was analyzed in 97 specimens. ATX, ERK, and AKT protein expression was studied by Western blotting. LPAR2 mRNA was overexpressed in HGSC cells in effusions compared to solid lesions, with opposite findings for LPAR3 and LPAR6 mRNA and ATX protein. Higher LPAR1 levels were significantly related to longer overall survival (OS) in pre-chemotherapy effusions (p = 0.027). Conversely, higher expression of LPAR1, LPAR2, and LPAR5 in post-chemotherapy effusions was significantly associated with shorter OS (p = 0.037, p = 0.025 and p = 0.021, respectively) and progression-free survival (PFS) (p < 0.001, p = 0.007 and p < 0.001, respectively) in univariate survival analysis. LPAR1 mRNA expression was an independent prognosticator of OS in patients with pre-chemotherapy effusions and PFS in patients with post-chemotherapy effusions (p = 0.013 both). In conclusion, LPAR mRNA and ATX protein levels are anatomic site-dependent in HGSC and the former are informative of disease outcome.
Literatur
1.
Zurück zum Zitat Torre LA, Bray F, Siegel RL, Ferlay J, Lortet-Tieulent J, Jemal A (2015) Global cancer statistics, 2012. CA Cancer J Clin 65:87–108CrossRef Torre LA, Bray F, Siegel RL, Ferlay J, Lortet-Tieulent J, Jemal A (2015) Global cancer statistics, 2012. CA Cancer J Clin 65:87–108CrossRef
2.
Zurück zum Zitat Davidson B (2016) Recently identified drug resistance biomarkers in ovarian cancer. Expert Rev Mol Diagn 16:569–578CrossRef Davidson B (2016) Recently identified drug resistance biomarkers in ovarian cancer. Expert Rev Mol Diagn 16:569–578CrossRef
3.
Zurück zum Zitat Aoki J, Inoue A, Okudaira S (2008) Two pathways for lysophosphatidic acid production. Biochim Biophys Acta 1781:513–518CrossRef Aoki J, Inoue A, Okudaira S (2008) Two pathways for lysophosphatidic acid production. Biochim Biophys Acta 1781:513–518CrossRef
4.
Zurück zum Zitat Xu Y, Shen Z, Wiper DW et al (1998) Lysophosphatidic acid as a potential marker for ovarian and other gynecologic cancers. JAMA 280:719–723CrossRef Xu Y, Shen Z, Wiper DW et al (1998) Lysophosphatidic acid as a potential marker for ovarian and other gynecologic cancers. JAMA 280:719–723CrossRef
5.
Zurück zum Zitat Goldsmith ZG, Ha JH, Jayaraman M, Dhanasekaran DN (2011) Lysophosphatidic acid stimulates the proliferation of ovarian cancer cells via the gep proto-oncogene Gα(12). Genes Cancer 2:563–575CrossRef Goldsmith ZG, Ha JH, Jayaraman M, Dhanasekaran DN (2011) Lysophosphatidic acid stimulates the proliferation of ovarian cancer cells via the gep proto-oncogene Gα(12). Genes Cancer 2:563–575CrossRef
6.
Zurück zum Zitat Okudaira S, Yukiura H, Aoki J (2010) Biological roles of lysophosphatidic acid signaling through its production by autotaxin. Biochimie 92:698–706CrossRef Okudaira S, Yukiura H, Aoki J (2010) Biological roles of lysophosphatidic acid signaling through its production by autotaxin. Biochimie 92:698–706CrossRef
7.
Zurück zum Zitat Yung YC, Stoddard NC, Chun J (2014) LPA receptor signaling: pharmacology, physiology, and pathophysiology. J Lipid Res 55:1192–1214CrossRef Yung YC, Stoddard NC, Chun J (2014) LPA receptor signaling: pharmacology, physiology, and pathophysiology. J Lipid Res 55:1192–1214CrossRef
8.
Zurück zum Zitat Murph MM, Liu W, Yu S et al (2009) Lysophosphatidic acid-induced transcriptional profile represents serous epithelial ovarian carcinoma and worsened prognosis. PLoS One 4:e5583CrossRef Murph MM, Liu W, Yu S et al (2009) Lysophosphatidic acid-induced transcriptional profile represents serous epithelial ovarian carcinoma and worsened prognosis. PLoS One 4:e5583CrossRef
9.
Zurück zum Zitat Tigyi G (2010) Aiming drug discovery at lysophosphatidic acid targets. Br J Pharmacol 161:241–270CrossRef Tigyi G (2010) Aiming drug discovery at lysophosphatidic acid targets. Br J Pharmacol 161:241–270CrossRef
10.
Zurück zum Zitat Ward JD, Ha JH, Jayaraman M, Dhanasekaran DN (2015) LPA-mediated migration of ovarian cancer cells involves translocalization of Gαi2 to invadopodia and association with Src and β-pix. Cancer Lett 356:382–391CrossRef Ward JD, Ha JH, Jayaraman M, Dhanasekaran DN (2015) LPA-mediated migration of ovarian cancer cells involves translocalization of Gαi2 to invadopodia and association with Src and β-pix. Cancer Lett 356:382–391CrossRef
11.
Zurück zum Zitat Yu S, Murph MM, Lu Y et al (2008) Lysophosphatidic acid receptors determine tumorigenicity and aggressiveness of ovarian cancer cells. J Natl Cancer Inst 100:1630–1642CrossRef Yu S, Murph MM, Lu Y et al (2008) Lysophosphatidic acid receptors determine tumorigenicity and aggressiveness of ovarian cancer cells. J Natl Cancer Inst 100:1630–1642CrossRef
12.
Zurück zum Zitat Kipps E, Tan DS, Kaye SB (2013) Meeting the challenge of ascites in ovarian cancer: new avenues for therapy and research. Nat Rev Cancer 13:273–282CrossRef Kipps E, Tan DS, Kaye SB (2013) Meeting the challenge of ascites in ovarian cancer: new avenues for therapy and research. Nat Rev Cancer 13:273–282CrossRef
13.
Zurück zum Zitat Bai CQ, Yao YW, Liu CH et al (2014) Diagnostic and prognostic significance of lysophosphatidic acid in malignant pleural effusions. J Thorac Dis 6:483–490PubMedPubMedCentral Bai CQ, Yao YW, Liu CH et al (2014) Diagnostic and prognostic significance of lysophosphatidic acid in malignant pleural effusions. J Thorac Dis 6:483–490PubMedPubMedCentral
14.
Zurück zum Zitat Venkatraman G, Benesch MG, Tang X, Dewald J, McMullen TP, Brindley DN (2015) Lysophosphatidate signaling stabilizes Nrf2 and increases the expression of genes involved in drug resistance and oxidative stress responses: implications for cancer treatment. FASEB J 29:772–785CrossRef Venkatraman G, Benesch MG, Tang X, Dewald J, McMullen TP, Brindley DN (2015) Lysophosphatidate signaling stabilizes Nrf2 and increases the expression of genes involved in drug resistance and oxidative stress responses: implications for cancer treatment. FASEB J 29:772–785CrossRef
15.
Zurück zum Zitat Jeong KJ, Park SY, Seo JH et al (2008) Lysophosphatidic acid receptor 2 and Gi/Src pathway mediate cell motility through cyclooxygenase 2 expression in CAOV-3 ovarian cancer cells. Exp Mol Med 40:607–616CrossRef Jeong KJ, Park SY, Seo JH et al (2008) Lysophosphatidic acid receptor 2 and Gi/Src pathway mediate cell motility through cyclooxygenase 2 expression in CAOV-3 ovarian cancer cells. Exp Mol Med 40:607–616CrossRef
16.
Zurück zum Zitat Gotoh M, Fujiwara Y, Yue J et al (2012) Controlling cancer through the autotaxin-lysophosphatidic acid receptor axis. Biochem Soc Trans 40:31–36CrossRef Gotoh M, Fujiwara Y, Yue J et al (2012) Controlling cancer through the autotaxin-lysophosphatidic acid receptor axis. Biochem Soc Trans 40:31–36CrossRef
17.
Zurück zum Zitat Willier S, Butt E, Grunewald TG (2013) Lysophosphatidic acid (LPA) signalling in cell migration and cancer invasion: a focussed review and analysis of LPA receptor gene expression on the basis of more than 1700 cancer microarrays. Biol Cell 105:317–333CrossRef Willier S, Butt E, Grunewald TG (2013) Lysophosphatidic acid (LPA) signalling in cell migration and cancer invasion: a focussed review and analysis of LPA receptor gene expression on the basis of more than 1700 cancer microarrays. Biol Cell 105:317–333CrossRef
18.
Zurück zum Zitat Liu S, Murph M, Panupinthu N, Mills GB (2009) ATX-LPA receptor axis in inflammation and cancer. Cell Cycle 8:3695–3701CrossRef Liu S, Murph M, Panupinthu N, Mills GB (2009) ATX-LPA receptor axis in inflammation and cancer. Cell Cycle 8:3695–3701CrossRef
19.
Zurück zum Zitat Blackburn J, Mansell JP (2012) The emerging role of lysophosphatidic acid (LPA) in skeletal biology. Bone 50:756–762CrossRef Blackburn J, Mansell JP (2012) The emerging role of lysophosphatidic acid (LPA) in skeletal biology. Bone 50:756–762CrossRef
20.
Zurück zum Zitat Tsujiuchi T, Hirane M, Dong Y, Fukushima N (2014) Diverse effects of LPA receptors on cell motile activities of cancer cells. J Recept Signal Transduct Res 34:149–153CrossRef Tsujiuchi T, Hirane M, Dong Y, Fukushima N (2014) Diverse effects of LPA receptors on cell motile activities of cancer cells. J Recept Signal Transduct Res 34:149–153CrossRef
21.
Zurück zum Zitat Westermann AM, Havik E, Postma FR et al (1998) Malignant effusions contain lysophosphatidic acid (LPA)-like activity. Ann Oncol 9:437–442CrossRef Westermann AM, Havik E, Postma FR et al (1998) Malignant effusions contain lysophosphatidic acid (LPA)-like activity. Ann Oncol 9:437–442CrossRef
22.
Zurück zum Zitat Ward JD, Dhanasekaran DN (2012) LPA stimulates the phosphorylation of p130Cas via Gαi2 in ovarian cancer cells. Genes Cancer 3:578–591CrossRef Ward JD, Dhanasekaran DN (2012) LPA stimulates the phosphorylation of p130Cas via Gαi2 in ovarian cancer cells. Genes Cancer 3:578–591CrossRef
23.
Zurück zum Zitat Lengyel E (2013) Ovarian cancer development and metastasis. Am J Pathol 177:1053–1064CrossRef Lengyel E (2013) Ovarian cancer development and metastasis. Am J Pathol 177:1053–1064CrossRef
24.
Zurück zum Zitat Ahmed N, Stenvers KL (2013) Getting to know ovarian cancer ascites: opportunities for targeted therapy-based translational research. Front Oncol 3:256CrossRef Ahmed N, Stenvers KL (2013) Getting to know ovarian cancer ascites: opportunities for targeted therapy-based translational research. Front Oncol 3:256CrossRef
25.
Zurück zum Zitat Davidson B, Firat P, Michael CW (eds) (2018) Serous effusions, 2nd edn. Springer, London Davidson B, Firat P, Michael CW (eds) (2018) Serous effusions, 2nd edn. Springer, London
26.
Zurück zum Zitat Wang H, Liu W, Wei D, Hu K, Wu X, Yao Y (2014) Effect of the LPA-mediated CXCL12-CXCR4 axis in the tumor proliferation, migration and invasion of ovarian cancer cell lines. Oncol Lett 7:1581–1585CrossRef Wang H, Liu W, Wei D, Hu K, Wu X, Yao Y (2014) Effect of the LPA-mediated CXCL12-CXCR4 axis in the tumor proliferation, migration and invasion of ovarian cancer cell lines. Oncol Lett 7:1581–1585CrossRef
27.
Zurück zum Zitat Fujita T, Miyamoto S, Onoyama I, Sonoda K, Mekada E, Nakano H (2003) Expression of lysophosphatidic acid receptors and vascular endothelial growth factor mediating lysophosphatidic acid in the development of human ovarian cancer. Cancer Lett 192:161–169CrossRef Fujita T, Miyamoto S, Onoyama I, Sonoda K, Mekada E, Nakano H (2003) Expression of lysophosphatidic acid receptors and vascular endothelial growth factor mediating lysophosphatidic acid in the development of human ovarian cancer. Cancer Lett 192:161–169CrossRef
28.
Zurück zum Zitat Wang P, Wu X, Chen W, Liu J, Wang X (2007) The lysophosphatidic acid (LPA) receptors their expression and significance in epithelial ovarian neoplasms. Gynecol Oncol 104:714–720CrossRef Wang P, Wu X, Chen W, Liu J, Wang X (2007) The lysophosphatidic acid (LPA) receptors their expression and significance in epithelial ovarian neoplasms. Gynecol Oncol 104:714–720CrossRef
29.
Zurück zum Zitat Yu X, Zhang Y, Chen H (2016) LPA receptor 1 mediates LPA-induced ovarian cancer metastasis: an in vitro and in vivo study. BMC Cancer 16:846CrossRef Yu X, Zhang Y, Chen H (2016) LPA receptor 1 mediates LPA-induced ovarian cancer metastasis: an in vitro and in vivo study. BMC Cancer 16:846CrossRef
30.
Zurück zum Zitat Seo EJ, Kwon YW, Jang IH et al (2016) Autotaxin regulates maintenance of ovarian cancer stem cells through lysophosphatidic acid-mediated autocrine mechanism. Stem Cells 34:551–564CrossRef Seo EJ, Kwon YW, Jang IH et al (2016) Autotaxin regulates maintenance of ovarian cancer stem cells through lysophosphatidic acid-mediated autocrine mechanism. Stem Cells 34:551–564CrossRef
31.
Zurück zum Zitat Boucharaba A, Serre CM, Guglielmi J, Bordet JC, Clézardin P, Peyruchaud O (2006) The type 1 lysophosphatidic acid receptor is a target for therapy in bone metastases. Proc Natl Acad Sci U S A 103:9643–9648CrossRef Boucharaba A, Serre CM, Guglielmi J, Bordet JC, Clézardin P, Peyruchaud O (2006) The type 1 lysophosphatidic acid receptor is a target for therapy in bone metastases. Proc Natl Acad Sci U S A 103:9643–9648CrossRef
32.
Zurück zum Zitat Tokumura A, Kume T, Fukuzawa K et al (2007) Peritoneal fluids from patients with certain gynecologic tumor contain elevated levels of bioactive lysophospholipase D activity. Life Sci 80:1641–1649CrossRef Tokumura A, Kume T, Fukuzawa K et al (2007) Peritoneal fluids from patients with certain gynecologic tumor contain elevated levels of bioactive lysophospholipase D activity. Life Sci 80:1641–1649CrossRef
33.
Zurück zum Zitat Murph M, Tanaka T, Pang J et al (2007) Liquid chromatography mass spectrometry for quantifying plasma lysophospholipids: potential biomarkers for cancer diagnosis. Methods Enzymol 433:1–25CrossRef Murph M, Tanaka T, Pang J et al (2007) Liquid chromatography mass spectrometry for quantifying plasma lysophospholipids: potential biomarkers for cancer diagnosis. Methods Enzymol 433:1–25CrossRef
Metadaten
Titel
Activity and clinical relevance of autotaxin and lysophosphatidic acid pathways in high-grade serous carcinoma
verfasst von
Hadil Onallah
Liora Jacobs Catane
Claes G. Tropé
Thea E. Hetland Falkenthal
Reuven Reich
Ben Davidson
Publikationsdatum
21.07.2018
Verlag
Springer Berlin Heidelberg
Erschienen in
Virchows Archiv / Ausgabe 4/2018
Print ISSN: 0945-6317
Elektronische ISSN: 1432-2307
DOI
https://doi.org/10.1007/s00428-018-2418-x

Weitere Artikel der Ausgabe 4/2018

Virchows Archiv 4/2018 Zur Ausgabe

Neu im Fachgebiet Pathologie

Molekularpathologische Untersuchungen im Wandel der Zeit

Open Access Biomarker Leitthema

Um auch an kleinen Gewebeproben zuverlässige und reproduzierbare Ergebnisse zu gewährleisten ist eine strenge Qualitätskontrolle in jedem Schritt des Arbeitsablaufs erforderlich. Eine nicht ordnungsgemäße Prüfung oder Behandlung des …

Vergleichende Pathologie in der onkologischen Forschung

Pathologie Leitthema

Die vergleichende experimentelle Pathologie („comparative experimental pathology“) ist ein Fachbereich an der Schnittstelle von Human- und Veterinärmedizin. Sie widmet sich der vergleichenden Erforschung von Gemeinsamkeiten und Unterschieden von …

Gastrointestinale Stromatumoren

Open Access GIST CME-Artikel

Gastrointestinale Stromatumoren (GIST) stellen seit über 20 Jahren ein Paradigma für die zielgerichtete Therapie mit Tyrosinkinaseinhibitoren dar. Eine elementare Voraussetzung für eine mögliche neoadjuvante oder adjuvante Behandlung bei …

Personalisierte Medizin in der Onkologie

Aufgrund des erheblichen technologischen Fortschritts in der molekularen und genetischen Diagnostik sowie zunehmender Erkenntnisse über die molekulare Pathogenese von Krankheiten hat in den letzten zwei Jahrzehnten ein grundlegender …